

# Marco Tagliamento

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1178177/marco-tagliamento-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53  
papers

778  
citations

16  
h-index

26  
g-index

74  
ext. papers

1,318  
ext. citations

5.3  
avg, IF

4.51  
L-index

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 53 | Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer.. <i>JCO Global Oncology</i> , <b>2022</b> , 8, e21007   | 2.7  | 153       |
| 52 | A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 172, 103639                              | 7    | 1         |
| 51 | Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 33-37   | 7.5  | 0         |
| 50 | The use of immunotherapy in older patients with advanced non-small cell lung cancer.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 106, 102394   | 14.4 | 1         |
| 49 | Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , <b>2021</b> , 1   | 4.4  | 8         |
| 48 | Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1669-1680      | 21.7 | 20        |
| 47 | Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. <i>JAMA Oncology</i> , <b>2021</b> ,  | 13.4 | 13        |
| 46 | Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , <b>2021</b> , | 7.5  | 18        |
| 45 | Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,  | 6.3  | 9         |
| 44 | Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. <i>Immunotherapy</i> , <b>2021</b> , 13, 509-525   | 3.8  | 1         |
| 43 | Mortality in adult patients with solid or hematological cancers and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e18608-e18608             | 2.2  |           |
| 42 | Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. <i>Breast Cancer: Targets and Therapy</i> , <b>2021</b> , 13, 341-351  | 3.9  | 0         |
| 41 | Safety of using hormone replacement therapy in breast cancer survivors: A systematic review and metanalysis.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 12067-12067   | 2.2  |           |
| 40 | Cancer pathways analysis and correlation with survival in patients with advanced stage non-small cell lung cancer treated with PD-1 inhibitor.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21007-e21007   | 2.2  |           |
| 39 | The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , <b>2021</b> , 13,   | 6.6  | 5         |
| 38 | VISTA: A Promising Target for Cancer Immunotherapy?. <i>ImmunoTargets and Therapy</i> , <b>2021</b> , 10, 185-200   | 9    | 5         |
| 37 | Heterogeneity of treatment effects in malignant pleural mesothelioma. <i>Lancet, The</i> , <b>2021</b> , 398, 301-302   | 40   | 1         |

|    |   |      |    |
|----|---|------|----|
| 36 | Radiomic Detection of EGFR Mutations in NSCLC. <i>Cancer Research</i> , <b>2021</b> , 81, 724-731   | 10.1 | 15 |
| 35 | Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , <b>2021</b> , 7, 162-172   | 3.7  | 16 |
| 34 | Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 163, 103365 | 7    | 15 |
| 33 | Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. <i>European Journal of Clinical Investigation</i> , <b>2021</b> , e13668  | 4.6  | 1  |
| 32 | 1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a national survey. <i>Annals of Oncology</i> , <b>2020</b> , 31, S1002-S1003                              | 10.3 | 78 |
| 31 | Update on the Management of Breast Cancer during Pregnancy. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  | 7  |
| 30 | Call for ensuring cancer care continuity during COVID-19 pandemic. <i>ESMO Open</i> , <b>2020</b> , 5, e000783  | 6    | 18 |
| 29 | Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , <b>2020</b> , 12,   | 6.6  | 27 |
| 28 | Performance of the OncoPrint™ Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice. <i>Applied Sciences (Switzerland)</i> , <b>2020</b> , 10, 2895  | 2.6  | 4  |
| 27 | Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , <b>2020</b> , 50, e13315  | 4.6  | 21 |
| 26 | Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 125   | 8.4  | 22 |
| 25 | Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, e1304-e1314  | 2.3  | 26 |
| 24 | Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2020</b> , 14, 1179554920931816  | 1.8  | 2  |
| 23 | ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 679-686  | 4    | 1  |
| 22 | Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 1603-1610  | 3.6  | 2  |
| 21 | Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies. <i>Blood</i> , <b>2020</b> , 136, 13-14   | 2.2  |    |
| 20 | Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , <b>2020</b> , 14, 367-383  | 3.8  | 11 |
| 19 | Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients. <i>Breast Cancer: Basic and Clinical Research</i> , <b>2020</b> , 14, 1178223420954179   | 2.2  | 9  |

|    |  |      |     |
|----|--|------|-----|
| 18 | Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , <b>2020</b> , 5,  | 6    | 18  |
| 17 | Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. <i>European Journal of Cancer</i> , <b>2020</b> , 139, 43-50  | 7.5  | 147 |
| 16 | New emerging targets in cancer immunotherapy: the role of VISTA. <i>ESMO Open</i> , <b>2020</b> , 4, e000683   | 6    | 13  |
| 15 | Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,   | 5.1  | 17  |
| 14 | Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 513-523          | 5.9  | 11  |
| 13 | The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. <i>Journal of Translational Medicine</i> , <b>2019</b> , 17, 74                                  | 8.5  | 41  |
| 12 | Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. <i>Immunotherapy</i> , <b>2019</b> , 11, 873-879   | 3.8  | 10  |
| 11 | Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , <b>2019</b> , 36, 449-456                        | 4.7  | 8   |
| 10 | Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 1351-1358   | 7.4  | 12  |
| 9  | Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,                      | 5.1  | 21  |
| 8  | PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e13098-e13098 | 2.2  | 1   |
| 7  | Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 2055-2062   | 4    | 18  |
| 6  | The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1969-1976   | 4    | 16  |
| 5  | Single-agent PARP inhibitors for the treatment of patients with -mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , <b>2018</b> , 3, e000361                                    | 6    | 41  |
| 4  | CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 829-835   | 5.4  | 8   |
| 3  | Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 551-561   | 5.9  | 4   |
| 2  | Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 573-585   | 4.1  | 16  |
| 1  | Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression. <i>Annals of Oncology</i> , <b>2017</b> , 28, vi61  | 10.3 | 2   |

